Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.
Squamous Cell Carcinoma of the Oral Cavity
DRUG: GL-0817|DRUG: Hiltonol|DRUG: Sargramostim|DRUG: cyclophosphamide|DRUG: Placebo
Disease-free interval, Up to 2 years
Disease-free survival (DFS), up to 2 years|Overall survival (OS), up to 5 years|Disease-free interval in a per protocol analysis, up to 2 years|Adverse event profile, up to week 94
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.